Literature DB >> 32621027

Prognostic performance of magnetic resonance imaging-guided biopsy in defining prostate cancer anterior lesions.

Angelo Porreca1, Federico Mineo Bianchi2, Antonio Salvaggio1, Daniele D'Agostino1, Alessandro Del Rosso1, Daniele Romagnoli1, Paolo Corsi1, Michele Colicchia1, Umberto Barbaresi2, Lorenzo Bianchi2, Marco Giampaoli2, Riccardo Schiavina2, Katie Palmer3, Francesco Del Giudice4, Martina Maggi4, Matteo Ferro5, Alessandro Sciarra4, Ettore De Berardinis4, Gian Maria Busetto6.   

Abstract

PURPOSE: Diagnosis of anterior prostate cancer (PCa) can be quite challenging, often leading to delay in treatment. mpMRI-guided biopsy (GB) has been introduced aiming to increase the number of diagnoses of clinically significant PCa with fewer cores. The aim of our study is to compare pathological findings of prostate biopsy, In-bore or Fusion technique, with histopathological evaluation of radical prostatectomy.
METHODS: We prospectively collected data from 90 consecutive patients who underwent either In-bore or Fusion biopsy following the detection of an index suspicious lesion at mpMRI in the anterior part of the prostatic gland. Bioptical pathological findings were compared with pathological findings reported after robot-assisted radical prostatectomy.
RESULTS: Patients who underwent In-bore GB had a higher rate of previous negative prostate biopsies (19% vs 44%, p = 0.02). Median number of bioptic cores taken (13 vs 2) and number of positive cores (3 vs 2) were significantly superior in the Fusion group compared to the In-bore group (p < 0.001 and p = 0.002, respectively), whilst clinical International Society of Urological Pathology (ISUP) grade was homogeneous within groups. The concordance between anterior lesions detected at biopsy and those reported in the histopathological finding of radical prostatectomy was very high, without statistically significant difference between groups.
CONCLUSION: Both Fusion and In-bore GB are accurate in detecting anterior PCa, with enhanced precision detecting clinically significant tumours, as evidenced by pathologic examinations which confirmed the presence of index anterior PCa in > 50% of patients overall. Additional sextant biopsy is still required, especially among biopsy-näive patients, to avoid missing clinically significant PCa.

Entities:  

Keywords:  Anterior lesions; Fusion prostate biopsy; In-bore prostate biopsy; Multiparametric magnetic resonance; Prostate cancer

Year:  2020        PMID: 32621027     DOI: 10.1007/s00345-020-03335-4

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  3 in total

1.  Multicenter analysis of pathological outcomes of patients eligible for active surveillance according to PRIAS criteria.

Authors:  Angelica A Grasso; Gabriele Cozzi; Elisa DE Lorenzis; Carlo Ceruti; Simone Crivellaro; Mario Falsaperla; Andrea Minervini; Lorenzo Masieri; Angelo Porreca; Stefano Zaramella; Bernardo Rocco
Journal:  Minerva Urol Nefrol       Date:  2015-03-03       Impact factor: 3.720

Review 2.  State of the art of PET/CT with 11-choline and 18F-fluorocholine in the diagnosis and follow-up of localized and locally advanced prostate cancer.

Authors:  Valerio Vagnoni; Eugenio Brunocilla; Lorenzo Bianchi; Angelo Porreca; Marco Borghesi; Cristian Vincenzo Pultrone; Porreca Angelo; Francesco Chessa; Francesco Ceci; Francesco Mengoni; Hussam Dababneh; Paolo Castellucci; Stefano Fanti; Giuseppe Martorana; Riccardo Schiavina
Journal:  Arch Esp Urol       Date:  2015-04       Impact factor: 0.436

3.  Which Drug to Discontinue 3 Months After Combination Therapy of Tadalafil plus Tamsulosin for Men with Lower Urinary Tract Symptom and Erectile Dysfunction? Results of a Prospective Observational Trial.

Authors:  Arcangelo Sebastianelli; Pietro Spatafora; Jacopo Frizzi; Omar Saleh; Cosimo De Nunzio; Andrea Tubaro; Linda Vignozzi; Mario Maggi; Sergio Serni; Kevin T McVary; Steven A Kaplan; Stavros Gravas; Christopher Chapple; Mauro Gacci
Journal:  Eur Urol Focus       Date:  2019-10-10
  3 in total
  4 in total

1.  Concordance of MRI-Guided Fusion and Systematic 12-Core Prostate Biopsy for the Detection of Prostate Cancer.

Authors:  Matthew Parsons; Zoya Sandhu; Bridget Foy; Ernest Chan; Bryan Crawford; Libby Petersen; Benjamin Romney; Daniel Sommers; Jay Bishoff; Steven Lynch; Logan Mclean; David Gill
Journal:  Front Oncol       Date:  2022-05-27       Impact factor: 5.738

2.  Influence of operative time and blood loss on surgical margins and functional outcomes for laparoscopic versus robotic-assisted radical prostatectomy: a prospective analysis.

Authors:  Stefano Salciccia; Davide Rosati; Pietro Viscuso; Vittorio Canale; Emiliano Scarrone; Marco Frisenda; Roberta Catuzzi; Martina Moriconi; Vincenzo Asero; Stefano Signore; Mauro De Dominicis; Paolo Emiliozzi; Antonio Carbone; Antonio Luigi Pastore; Andrea Fuschi; Giovanni Battista Di Pierro; Alessandro Gentilucci; Susanna Cattarino; Gianna Mariotti; Gian Maria Busetto; Matteo Ferro; Ettore De Berardinis; Gian Piero Ricciuti; Valeria Panebianco; Fabio Massimo Magliocca; Francesco Del Giudice; Martina Maggi; Alessandro Sciarra
Journal:  Cent European J Urol       Date:  2021-11-29

3.  Bi-parametric MRI/TRUS fusion targeted repeat biopsy after systematic 10-12 core TRUS-guided biopsy reveals more significant prostate cancer especially in anteriorly located tumors.

Authors:  Michael Häggman; Pär Dahlman; Mats Ahlberg; Per Liss; Rafaele Cantera Ahlman; Anca Dragomir; Sam Ladjevardi
Journal:  Acta Radiol Open       Date:  2022-03-31

Review 4.  Radiomics in prostate cancer: an up-to-date review.

Authors:  Matteo Ferro; Ottavio de Cobelli; Gennaro Musi; Francesco Del Giudice; Giuseppe Carrieri; Gian Maria Busetto; Ugo Giovanni Falagario; Alessandro Sciarra; Martina Maggi; Felice Crocetto; Biagio Barone; Vincenzo Francesco Caputo; Michele Marchioni; Giuseppe Lucarelli; Ciro Imbimbo; Francesco Alessandro Mistretta; Stefano Luzzago; Mihai Dorin Vartolomei; Luigi Cormio; Riccardo Autorino; Octavian Sabin Tătaru
Journal:  Ther Adv Urol       Date:  2022-07-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.